Italy to Be First Beneficiary of EU Malaria Fund: Siena-Based Achilles Vaccines srl to Receive Financing to Fight Malaria and COVID-19
The EU Malaria Fund (EUMF) yesterday presented its first investment into Achilles Vaccines srl at the premises of Fondazione Monte dei Paschi di Siena in Italy. The investment supports development of a novel Malaria vaccine on its versatile technology platform transforming bacteria, natural carriers of molecules harmful to human health, into an efficient delivery system of bio antigenic molecules to produce low-cost, safe and self-adjuvanting fit-for-purpose vaccines. The EUMF funding, with support from Fondazione TLS, will also be used to advance Achilles’ project to develop a novel human monoclonal antibody against COVID-19.
The first recipient of EUMF funding, Achilles, is a Siena-based biotech company specialising in research on malaria, antimicrobial resistance and, lately, COVID-19. “Achilles Vaccines is proud to contribute to the search for vaccines to eliminate malaria, a disease that faded into the background in these dramatic months, but which still claims significantly more victims than COVID-19 does, especially among children. Thanks to the guidance of Dr Rappuoli, we escape the challenge of finding a therapeutic and prophylactic drug with our monoclonal antibody, that finally makes the pandemic in which we find ourselves manageable”, said Riccardo Baccheschi, President and CEO of Achilles.
Holm Keller, Managing Director of EUMF and Chairman of kENUP Foundation said: “The EU Malaria Fund has high hopes, that the investment at the heart of the Siena vaccine hub in Italy will help to accelerate the eradication of Malaria. I am delighted that in these trying times, innovative Italian companies, like Achilles, will play a role in developing solutions against COVID-19".
The European Commission and the European Investment Bank (EIB) are investing €111 million into the fund. “Vaccines are important for disease prevention,” said Ambroise Fayolle, EIB Vice President in charge of innovation. “But often they also generate lower revenues than drugs and other health care services and are thus less attractive for private investors. This is why initiatives like the EU Malaria Fund are so important. We are glad to see the first investment of this Fund materialise so quickly and hope that it will allow AchilleS to progress in this important field of research.”
“We are very proud to be the first Italian foundation to invest in the EU Malaria Fund. With a 1 million euros amount, the Fondazione MPS is pursuing two main goals in a long-term vision: supporting scientific research for those diseases that have a big impact on public health and attracting financial resources with long-term benefits for the province of Siena. – said Carlo Rossi, Chairman of Fondazione Monte dei Paschi di Siena, “We also appreciate that the EU Malaria Fund will support the COVID-19 research, as it represents, at the moment, the most important worldwide sanitary challenge that requires huge common efforts”.
The EIB and WHO support the development of the EU Malaria Fund. “Together with WHO’s technical expertise we are confident of accelerating the development of new and innovative tools. The first investment of the EU Malaria Fund in Achilles will meaningfully advance the renewed efforts in our fight against Malaria” said Dr Pedro Alonso, Director of the World Health Organisation’s Global Malaria Programme.
The EUMF is a public-private partnership between the European Union, international organisations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. Further information can be found at www.controlMalaria.eu.
The video of the event can be found at https://www.controlmalaria.eu/news
+ 39 347.7467250
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA ® (lefamulin)6.7.2020 13:00:00 CEST | Press release
WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA® (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is designed to ensure that physicians, contingent on meeting the necessary eligibility criteria and receiving approval, can request IV or oral XENLETA on behalf of patients who live in certain countries where it is not yet available. XENLETA was discovered and developed by Nabriva (NASDAQ: NBRV), a commercial-stage biopharmaceutical company focused on commercialization and development of anti-infective agents. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. XENLETA is the first and only oral and IV pleuromutilin empiric antibiotic that acts against the pathogens that commonly cause CABP. Nabriva announced on May 29th
Pudu Robotics Raised over $15M Series B Financing with Meituan as the Exclusive Investor6.7.2020 11:11:00 CEST | Press release
On July 1, 2020, Pudu Robotics, an indoor delivery robot provider, officially announced the completion of B round financing of more than $15M with Meituan as the exclusive investor. Zhang Tao, CEO of Pudu Robotics, said the fund would be mainly used to develop products, expand sales, explore new usage scenarios and expand overseas market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005180/en/ (Photo: Business Wire) Pudu Robotics is a top-notch intelligent indoor delivery robot provider in China. The company focuses on the R&D, design and production of robots and offers a number of popular delivery robots, including PuduBot (food delivery robot), BellaBot (food delivery robot), HoloBot (building delivery robot), HolaBot (dish-return robot), and GazeBot (multi-scene delivery robot). Its first mass-produced robot PuduBot has been widely used in extensive scenarios, including restaurants, hotels, office buildings, hospi
Seoul Semiconductor’s SunLike Natural Spectrum LEDs Adopted by Fiberli Grow Light for Horticulture Projects in Turkey6.7.2020 11:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been adopted for horticulture LED lighting by the lighting solution company Fiberli, located in Turkey, one of the largest agricultural exporters in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005073/en/ Seoul Semiconductor’s SunLike Natural Spectrum LEDs Adopted by Fiberli Grow Light for Horticulture Projects in Turkey (Photo: Business Wire) While it is well known that natural sunlight is one of the key factors in growth cycle of a plant, most growers cultivating a variety of crops under sunlight have experienced difficulties in regulating their growth cycles due to adverse seasonal conditions. Replacing sunlight with LED lighting that closely matches natural sunlight enables growers to control the growth cycles and development of all types
Sabio Group Acquires Coverage Group in France6.7.2020 10:00:00 CEST | Press release
Sabio Group has announced the acquisition of Coverage Group, one of France’s leading independent providers of customer experience and communications technology solutions. The acquisition supports Sabio’s goal of becoming the leading player across the European CX market and will add significant scale to the company’s French operations. Formed in 2007, Paris-based Coverage Group is an established Genesys Gold, Avaya Edge, Oracle Gold and Broadsoft technology partner. The company has a proven track record in helping organisations across France to place cloud-based customer experience solutions at the heart of their digital strategy, with customers including ENGIE, BEA, EBP, Emil Frey, Homeserve, NutriXo, Optimind, Pierre Fabre, Pierre & Vacances, Sitel and Teleperformance. “The acquisition is a massively important strategic addition for Sabio Group and our customers in a number of ways – it means we have now built a substantial presence and customer base in France, it further strengthens
BearingPoint helps government and public sector organizations deliver critical health and public services during the Covid-19 pandemic6.7.2020 09:00:00 CEST | Press release
Management and technology consultancy BearingPoint announced today that it is helping its government and public sector clients across Europe to deliver critical health and public services during the Covid-19 pandemic through new delivery models, new ways of working, digitalization, and automation. “BearingPoint’s organization as a single, European-based business has meant we have been able to draw on capabilities, leading practices and learnings from across our government and public sector clients and teams in many different countries. Working remotely and in partnership with our clients, we have quickly mobilized resources to design and deliver solutions to support both the public services needed during Covid-19 and the new ways of working for public servants,” said Andrew Montgomery, Partner and Global Leader Government and Public Sector at BearingPoint. New delivery models and services People’s health and well-being during the Covid-19 crisis have required public services to rapidly
Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe6.7.2020 08:00:00 CEST | Press release
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services. Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom